QUAD is marketed by MEDVi as a sublingual, four-drug cocktail for erectile dysfunction, combining three well-known PDE5 inhibitors—sildenafil, tadalafil, and…
Read More
New York Times-lauded Medvi is marketing QUAD, a four-drug ED cocktail with a Parkinson’s drug component
The digital health company MEDVi, recently spotlighted in an April 2 New York Times profile that depicted CEO Matthew Gallagher…
Read More
Long-Term Residential Exposure to Chlorpyrifos Linked to Significant Increase in Parkinson’s Disease Risk According to New UCLA Health Study
A comprehensive study led by researchers at UCLA Health has established a definitive link between long-term residential exposure to the…
Read More
Long-Term Residential Exposure to Chlorpyrifos Increases Parkinson’s Disease Risk by Over Two and a Half Times UCLA Health Study Finds
A groundbreaking longitudinal study conducted by researchers at UCLA Health has established a definitive link between chronic residential exposure to…
Read More
Plastic waste transformed into Parkinson’s drug in bioengineering first
A groundbreaking innovation emerging from The University of Edinburgh in the United Kingdom has unveiled a novel technology capable of…
Read More
Long-Term Exposure to Chlorpyrifos Linked to Significantly Higher Risk of Parkinson’s Disease According to UCLA Health Study
A comprehensive study led by researchers at UCLA Health has established a definitive link between long-term residential exposure to the…
Read More
Parkinson’s Disease Research Reaches Pivotal Point Amidst Funding and Trial Hurdles
The scientific understanding of Parkinson’s disease (PD) has advanced significantly, placing preclinical and clinical research at a critical juncture. However,…
Read More
Microplastics and Neurodegeneration: New Research Links Synthetic Particles to Alzheimer’s and Parkinson’s Disease Risks
The global escalation of plastic pollution has long been recognized as a primary threat to marine ecosystems and environmental stability,…
Read More
